BibTeX
@MISC{Klefter_musclemass,
author = {Oliver Klefter and Ulla Feldt-rasmussen},
title = {Muscle Mass},
year = {}
}
Share
 |
 |
 |
 |
||
OpenURL
Abstract
Objective: Adult patients with growth hormone (GH) deficiency (GHD) are characterised by a reduced muscle mass, but also reduced bone mineral density (BMD) and content (BMC), which have been ascribed to GHD per se. The aim of this study was to investigate if changes in BMD/BMC in adult GHD patients could be due to a muscle modulating effect, and if treatment with GH would primarily increase muscle mass and strength with a secondary increase in BMD/BMC, thus supporting the current physiological concept that mass and strength of bones are mainly determined by dynamic loads from the skeletal muscles. Method: We performed a systematic literature analysis, including 51 clinical trials published between 1996-2008, which had studied the development in muscle mass, muscle strength, BMD and/or BMC in GH treated adult GHD patients. Results: GH therapy had an anabolic effect on skeletal muscle. The largest increase in muscle mass occurred during the first 12 months of therapy. Most trials measuring BMD/BMC reported significant increases from baseline values. The significant increases in BMD/BMC occurred after 12-18 months of treatment, i.e. usually later than
Keyphrases
muscle mass bmd bmc significant increase adult ghd patient skeletal muscle gh therapy bone mineral density growth hormone secondary increase baseline value reduced muscle mass current physiological concept anabolic effect dynamic load 12-18 month muscle strength clinical trial adult patient systematic literature analysis
